North America Sleep Disorder Treatment Market – Industry Trends and Forecast to 2028

Market Analysis and Insights: North America Sleep Disorder Treatment Market

North America sleep disorder treatment market is expected to reach USD 9,469.97 million by 2028, from USD 4,945.53 million in 2020, growing at the CAGR of 8.6% in the forecast period of 2021 to 2028. North America sleep disorder treatment market is expected to grow due the increased prevalence of sleep disorders such as sleep apnea, insomnia and narcolepsy across globe.

Sleep disorder such as sleep apnea, narcolepsy or insomnia are medical disorder in which the patient has difficulty with maintenance of sleep or sleep initiation. This disorder causes irregular mental, physical, social and emotional functions. Sleep disorders are treated via different treatment options according to the symptoms of the patients. Most of the sleep apnea patients are treated via mechanical therapies. Pharmacological therapies such as antidepressants, cannabidiols, benzodiazepines and stimulants are used for the treatment of insomnia, narcolepsy and restless legs syndrome among others. The intraoral devices are also used to prevent snoring by creating airway channel in order to create room for proper gas exchange.

The growth of the market is anticipated to be propelled by factors such as increasing incidences of depression & other medical disorders, rising geriatric population across globe, lifestyle changes, lack of quality sleep which have driven the sleep disorder treatment market growth. The introduction of new FDA approved drugs and medical devices for the treatment of such sleep disorder acts as an opportunity for the growth of the sleep disorder treatment market. However, patent expirations or patent cliff of major sleep disorder treatment drugs and side effects associated with these drugs restraint the sleep disorder treatment market growth.

The sleep disorder treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Sleep Disorder Treatment Market Scope and Market Size

North America sleep disorder treatment market is segmented on the basis of type, treatment, route of administration, drugs type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of type, the sleep disorder treatment market is segmented into insomnia, sleep apnea, restless legs syndrome (RLS), narcolepsy and others. In 2021, insomnia segment is dominating the market because of the growing awareness about the condition, more and more people are adopting the treatment options.
• On the basis of treatment, the sleep disorder treatment market is segmented into pharmacological therapy, mechanical therapy, mandibular advancement devices, hypoglossal nerve stimulator, surgery and others. In 2021, pharmacological therapy segment is dominating the market due to increased pipeline products for the treatment of sleep disorders by key market players.
• On the basis of route of administration, the sleep disorder treatment market is segmented into oral, parenteral and others. In 2021, oral segment is dominating the market due to the economical and safe form of administration leading to increased uptake by the suffered patients.
• On the basis of drugs type, the sleep disorder treatment market is segmented into branded and generics. In 2021, generics segment is dominating the market because of the economical nature and easy availability of the generics drugs for the treatment of sleep disorder.
• On the basis of population type, the sleep disorder treatment market is segmented into children and adults. In 2021, adults segment is dominating the market due to availability of the U.S. FDA approved pharmacological therapies for the treatment of sleep disorder in adults.
• On the basis of end user, the sleep disorder treatment market is segmented into hospitals, specialty clinics, home healthcare, ambulatory surgical center and others. In 2021, hospitals segment is dominating the market as hospitals are the prime location visited by patients for any procedure or surgery.
• On the basis of distribution channel, the sleep disorder treatment market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, direct tender segment is dominating the market because direct tender fulfils the need of physicians and patients as most of the facilities procure drugs from direct tenders.

Sleep Disorder Treatment Market Country Level Analysis

The sleep disorder treatment market is analysed and market size information is provided by the country, type, treatment, route of administration, drugs type, population type, end user, and distribution channel.

The countries covered in the sleep disorder treatment market report are the U.S., Canada and Mexico.

The U.S. is expected to dominate the market due to the increasing prevalence of sleep disorders among the population. Canada is expected to grow due to the increasing product portfolio of companies. Mexico is expected to grow because it is an emerging market and the market players are focusing more on providing different products.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

New product launches by manufactures is creating new opportunities for players in the sleep disorder treatment market

Sleep disorder treatment market also provides you with detailed market analysis for every country growth in sleep disorder treatment industry with sleep disorder treatment market sales, impact of advancement in the sleep disorder treatment market and changes in regulatory scenarios with their support for the sleep disorder treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Sleep Disorder Treatment Market Share Analysis

Sleep disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to sleep disorder treatment market.

Some of the major players operating in the sleep disorder treatment market are Jazz Pharmaceuticals, Inc., Pfizer Inc., Viatris Inc., Arbor Pharmaceuticals, Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), sanofi-aventis U.S. LLC (a subsidiary of Sanofi), Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Pharmaceuticals, Inc. (a subsidiary of Lupin), Taj Pharmaceuticals Limited, Eli Lilly and Company, Mallinckrodt, Alembic Pharmaceuticals Limited, Apotex Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Taro Pharmaceutical Industries Ltd., Koninklijke Philips N.V., DeVilbiss Healthcare LLC, ResMed, SomnoMed, Oventus and BMC Medical Co. among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the sleep disorder treatment market.

For instance,

• In July 2020, Jazz Pharmaceuticals plc announced the FDA approval for its drug named Xyway for the indication of both cataplexy and excessive daytime sleepiness in people living with narcolepsy for the age group of more than 15 years. This new sleep disorder therapeutic of the company approved by the U.S. FDA has increased the demand and sales for its drug in the market leading to increased revenue in future.
• In June 2016, Mylan N.V. has launched generic version of the drug nuvigil named armodafinil tablet for the indication of wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, narcolepsy or shift-work disorder. This new drug launched by the company in the U.S. market has increased its demand and sales in the market leading to increased sales in future.

SKU-59666